UNSPSC 51284104: Cefditoren

This classification denotes a cephalosporin antibiotic with the molecular formula C19H18N6O5S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 81QS09V3YW, chemically known as cefditoren pivoxil, me-1207, meiact but generally known as cefditoren, which bears US NIH Compound Identifier 444006. European Medicines Agency schedules Cefditoren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07387MIG.

UNSPSC 51284104 Cefditoren, a Commodity code, does not map to the state and local contract opportunities currently tagged under it. The recent solicitations show that Cefditoren—a narrow pharmaceutical product category naming a single cephalosporin antibiotic—is not what state and local governments are actually procuring under this code. Instead, the opportunities include Naloxone and drug deactivation systems, direct-to-manufacturer pharmacy benefit programs, emergency medical and first aid supplies, and multi-source generic pharmaceuticals and OTC products. These are substantially broader pharmaceutical procurement categories than the code's nominal scope. The mismatch suggests either miscoding at the issuing-body level or a UNSPSC taxonomy update lag; in practice, state and local buyers appear to use this code as a catch-all for various pharmaceutical acquisition approaches rather than specifically for cefditoren products.

The issuing bodies include a Florida county health department (Seminole County), a state HHS commission (Texas), a city fire department (Tampa), and a multistate cooperative purchasing alliance (MMCAP, Minnesota and Oregon). Recent opportunities range from direct IFB procurements for specific drug classes and emergency supplies to exploratory RFI activity around direct-to-manufacturer relationships. The geographic spread spans Texas, Florida, Minnesota, and Oregon. A Tampa Fire Department IFB (Bid 26-P-00145) sought 169 line items of medical and first aid supplies with an estimated contract value of $700,000 and a March 13, 2026 response deadline, designated as a sheltered market opportunity for certified Small Local Business Enterprises. MMCAP issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through three authorized wholesalers and comply with cGMP and DSCSA standards. Code activity appears episodic and misaligned with the nominal product category—monitor for clarity on actual procurement intent before building a pursuit strategy.